ArticleJTO clinical and research reports2024

Brief Report: Risk of Recurrent Interstitial Lung Disease From Osimertinib Versus Erlotinib Rechallenge After Symptomatic Osimertinib-Induced Interstitial Lung Disease.

Molly S C Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.